{"title":"AACAP on diversity, equity, inclusion, and belonging","authors":"Alison Knopf","doi":"10.1002/cpu30941","DOIUrl":"https://doi.org/10.1002/cpu30941","url":null,"abstract":"<p>The American Academy of Child and Adolescent Psychiatry (AACAP) is dedicated to ensuring equitable access to mental health resources and compassionate care for all children, adolescents and their families, regardless of their ability and identity, and has issued the following statement.</p>","PeriodicalId":22496,"journal":{"name":"The Brown University Child & Adolescent Psychopharmacology Update","volume":"27 2","pages":"8"},"PeriodicalIF":0.0,"publicationDate":"2025-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143114187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Treatment retention better with methadone than buprenorphine","authors":"Alison Knopf","doi":"10.1002/cpu30937","DOIUrl":"https://doi.org/10.1002/cpu30937","url":null,"abstract":"<p>A recent study comparing the effectiveness of buprenorphine and methadone found that the risk of discontinuation was greater with buprenorphine than methadone. For the study, the researchers looked at a retrospective cohort of patients via databases in British Columbia, Canada. The study covered a total of 30,891 patients, who received treatment from 2010 to 2020.</p>","PeriodicalId":22496,"journal":{"name":"The Brown University Child & Adolescent Psychopharmacology Update","volume":"27 2","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2025-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143114188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"FDA changes buprenorphine labeling to favor higher doses","authors":"","doi":"10.1002/cpu30940","DOIUrl":"https://doi.org/10.1002/cpu30940","url":null,"abstract":"<p>In December, the Food and Drug Administration (FDA) issued the Federal Register notice, Modifications to Labeling of Buprenorphine-Containing Transmucosal Products for the Treatment of Opioid Dependence, to encourage the submission of supplemental new drug applications to modify the labeling statements for buprenorphine-containing transmucosal products for the treatment of opioid dependence (BTODs). BTODs are medications that are dissolved in the mouth and contain buprenorphine, or a combination of buprenorphine and naloxone, and are indicated to treat opioid use disorder (OUD)—previously referred to as opioid dependence.</p>","PeriodicalId":22496,"journal":{"name":"The Brown University Child & Adolescent Psychopharmacology Update","volume":"27 2","pages":"6-8"},"PeriodicalIF":0.0,"publicationDate":"2025-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143114191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Age-specific providers needed for transition-age youth","authors":"Alison Knopf","doi":"10.1002/cpu30936","DOIUrl":"https://doi.org/10.1002/cpu30936","url":null,"abstract":"<p>“Transition-age youth” means those years when an adolescent turns into an adult. It's a gradual transition, but problems may arise, especially when there is no appropriate mental health care. It is a time when youth are particularly vulnerable to stress, and also when serious mental health problems can derail their move into adulthood. The years of being home and protected by parents, perhaps, are over. College, jobs, and concerns about the “real world” can take over. Furthermore, the inner world — depression, anxiety, suicide, substance use, bullying, romance, even possible first-episode psychosis which takes place during these years, can emerge. Medically, the pediatrician is probably leaving the child's medical team, and new providers — adult providers — will be taking over. These providers don't know the child the way the pediatrician does.</p>","PeriodicalId":22496,"journal":{"name":"The Brown University Child & Adolescent Psychopharmacology Update","volume":"27 2","pages":"1-3"},"PeriodicalIF":0.0,"publicationDate":"2025-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143114186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"LGB+ youth more likely to have major depression and suicidal thoughts","authors":"Alison Knopf","doi":"10.1002/cpu30928","DOIUrl":"https://doi.org/10.1002/cpu30928","url":null,"abstract":"<p>A new report from the Substance Abuse and Mental Health Services Administration (SAMHSA) has found that LGB+ youth are more likely than straight youth to have major depression and serious thoughts of suicide. <b>Behavioral Health of Adolescents Across Sexual Identities: Results from the 2023 National Survey on Drug Use and Health</b> (NSDUH), a new infographic report highlighting data pertaining to Lesbian, Gay, Bisexual and any non-heterosexual identifying youth, was released in November 2024.</p>","PeriodicalId":22496,"journal":{"name":"The Brown University Child & Adolescent Psychopharmacology Update","volume":"27 1","pages":"5"},"PeriodicalIF":0.0,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142861122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Confidentiality, clinicians, and parents in mental health care now","authors":"Alison Knopf","doi":"10.1002/cpu30933","DOIUrl":"https://doi.org/10.1002/cpu30933","url":null,"abstract":"<p>Right after the presidential election last fall, the outgoing pres-ident of the American Academy of Pediatrics listed the many ways in which the organization has protected children over the past year. Keeping health insurance and access to mental health care, promot-ing vaccine confidence, keeping children safe online, challenging bans on gender-affirming care and reproductive health services are just some of the important protections for children.</p>","PeriodicalId":22496,"journal":{"name":"The Brown University Child & Adolescent Psychopharmacology Update","volume":"27 1","pages":"7"},"PeriodicalIF":0.0,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142861143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Viloxazine moderate dose associated with good ADHD outcomes","authors":"Alison Knopf","doi":"10.1002/cpu30925","DOIUrl":"https://doi.org/10.1002/cpu30925","url":null,"abstract":"<p>Attention-deficit hyperactivity disorder (ADHD) is treated by medications, most recently, by viloxazine (Qelbree). Researchers in China looked at clinical trials to try to determine the best dose. Viloxazine was associated with better outcomes than placebo, with a bell-shaped response curve suggesting that doses greater than 400 mg or greater than 7 mg/kg might not be linked to greater efficacy. Ascent curves tapered off about weeks 4 to 6. The curve for only 100 mg/d declined more rapidly, while the curves for 200 mg/dl and 400 mg/dl declined more gradually. In terms of adverse effects, there was a higher risk of discontinuation with viloxazine compared to placebo. The discontinuation rates due to adverse effects was 4.15% in the viloxazine group.</p>","PeriodicalId":22496,"journal":{"name":"The Brown University Child & Adolescent Psychopharmacology Update","volume":"27 1","pages":"1-3"},"PeriodicalIF":0.0,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142861146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"ADHD medications with fewer adverse events would improve outcomes","authors":"Alison Knopf","doi":"10.1002/cpu30930","DOIUrl":"https://doi.org/10.1002/cpu30930","url":null,"abstract":"","PeriodicalId":22496,"journal":{"name":"The Brown University Child & Adolescent Psychopharmacology Update","volume":"27 1","pages":"6"},"PeriodicalIF":0.0,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142861124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}